Table 1.

Randomized controlled trials assessing cardioprotective regimes

Study	Year of publication	Study design	Cancer type	Chemotherapy type	Study drug	Sample size	Median age	% women	Mean LVEF difference (%)
Cardinale21	2006	RCT	Various	Various	Enalapril	56	47	60	9.7
					Control	58	44	67
Kalay13	2006	RCT	Various	Anthracycline	Carvedilol	25	46	88	17.4
					Placebo	25	49	84
Georgakopoulos25	2010	RCT	Lymphoma	Doxorubicin	Metoprolol	42	51	48	3.3
					Enalapril	43	47	49	2.8
					Control	40	49	47
Kaya14	2012	RCT	Breast cancer	Anthracycline	Nebivolol	27	51	100	6.3
					Control	18	50	100
Dessi22	2013	RCT	Various	Epirubicin	Telmisartan	25	52	76	4
					Placebo	24	53	75
Bosch27	2013	RCT	Haematological malignancies	Anthracycline and various	Enalapril and Carvedilol	45	49	40	2.2
					Control	45	50	47
Elitok15	2014	RCT	Breast cancer	Anthracycline	Carvedilol	40	54	100	0.8
					Placebo	40	52	100
Akpek29	2015	RCT	Breast cancer	Anthracycline and various	Spironolactone	43	50	100	12.1
					Placebo	40	50	100
Boekhout23	2016	RCT	Breast cancer	Anthracycline and Trastuzumab	Candesartan	103	50	100	1
					Placebo	103	50	100
Tashakori Beheshti17	2016	RCT	Breast cancer	Doxorubicin	Carvedilol	30	42	100	1.76
					Placebo	40	39	100
Jhorawat16	2016	RCT	Lymphoreticular malignancy	Adriamycin	Carvedilol	27	43	14.8	3
					Placebo	27	38	33.3
Pituskin26	2017	RCT	Breast cancer	Trastuzumab adjuvant	Perindopril	33	53	100	3
					Bisoprolol	31	50	100	5
					Placebo	30	51	100
Janbabai24	2017	RCT	Various	Anthracycline and various	Enalapril	34	47	97	13.6
					Placebo	35	47	88
Abuosa18	2018	RCT	Various	Doxorubicin	Carvedilol	37	42	77	1
					Placebo	38	40	76
Avila19	2018	RCT	Breast cancer	Anthracycline	Carvedilol	96	50	100	0
					Placebo	52	52	100
Cochera20	2018	RCT	Breast cancer	Doxorubicin	Nebivolol	30	53	100	1
					Placebo	30	52	100

LVEF, left ventricular ejection fraction; RCT, randomized controlled trial.